메뉴 건너뛰기




Volumn 97, Issue 1, 2007, Pages 27-31

Clot structure modification by fondaparinux and consequence on fibrinolysis: A new mechanism of antithrombotic activity

Author keywords

Clot structure; Fibrin network; Fibronolysis; Fondaparinux

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN;

EID: 33847072643     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-07-0394     Document Type: Article
Times cited : (21)

References (25)
  • 1
    • 18544385353 scopus 로고    scopus 로고
    • The synthetic pentasaccharide fondaparinux: First in the class of antithrombotic agents that selectively inhibit coagulation factor Xa
    • Petitou M, Duchaussoy P, Herbert JM, et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002; 28: 393-402.
    • (2002) Semin Thromb Hemost , vol.28 , pp. 393-402
    • Petitou, M.1    Duchaussoy, P.2    Herbert, J.M.3
  • 2
    • 0142182561 scopus 로고    scopus 로고
    • Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism
    • The Matisse Investigators
    • The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 867-73.
    • (2003) N Engl J Med , vol.349 , pp. 867-873
  • 3
    • 21944443716 scopus 로고    scopus 로고
    • The safety of fondaparinux for the prevention and treatment of venous thromboembolism
    • Turpie AG. The safety of fondaparinux for the prevention and treatment of venous thromboembolism. Expert Opin Drug Saf 2005; 4: 707-21.
    • (2005) Expert Opin Drug Saf , vol.4 , pp. 707-721
    • Turpie, A.G.1
  • 4
    • 33645497961 scopus 로고    scopus 로고
    • Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial
    • Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. J Am Med Assoc 2006; 295: 1519-30.
    • (2006) J Am Med Assoc , vol.295 , pp. 1519-1530
    • Yusuf, S.1    Mehta, S.R.2    Chrolavicius, S.3
  • 5
    • 22844436957 scopus 로고    scopus 로고
    • Short- and long-acting synthetic pentasaccharides as antithrombotic agents
    • Walenga JM, Jeske WP, Fareed J. Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Expert Opin Investig Drugs 2005; 14: 847-58.
    • (2005) Expert Opin Investig Drugs , vol.14 , pp. 847-858
    • Walenga, J.M.1    Jeske, W.P.2    Fareed, J.3
  • 6
    • 0016260116 scopus 로고
    • On the antithrombotic action of heparin
    • Wessler S. Yin ET. On the antithrombotic action of heparin. Thromb Diath Haemorrh 1974; 32: 71-8.
    • (1974) Thromb Diath Haemorrh , vol.32 , pp. 71-78
    • Wessler, S.1    Yin, E.T.2
  • 7
    • 0030952743 scopus 로고    scopus 로고
    • Biochemical and pharmacologic rationale for the development of a synthetic pentasaccharide
    • Walenga JM, Jeske WP, Bara L, et al. Biochemical and pharmacologic rationale for the development of a synthetic pentasaccharide. Thromb Res 1997; 86: 1-36.
    • (1997) Thromb Res , vol.86 , pp. 1-36
    • Walenga, J.M.1    Jeske, W.P.2    Bara, L.3
  • 8
    • 0027965921 scopus 로고
    • Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activation
    • Blomback B, Carlsson K, Fatah K, et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
    • (1994) Thromb Res , vol.75 , pp. 521-538
    • Blomback, B.1    Carlsson, K.2    Fatah, K.3
  • 9
    • 0028100450 scopus 로고
    • Fibrinogen structure, activation, polymerization and fibrin gel structure
    • Blomback B. Fibrinogen structure, activation, polymerization and fibrin gel structure. Thromb Res 1994; 75: 327-8.
    • (1994) Thromb Res , vol.75 , pp. 327-328
    • Blomback, B.1
  • 10
    • 0027517306 scopus 로고
    • Dusart syndrome: A new concept of the relationship between fibrin clot architecture and fibrin clot degradability: Hypofibrinolysis related to an abnormal clot structure
    • Collet JP, Soria J, Mirshahi M, et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82: 2462-9.
    • (1993) Blood , vol.82 , pp. 2462-2469
    • Collet, J.P.1    Soria, J.2    Mirshahi, M.3
  • 11
    • 0032765219 scopus 로고    scopus 로고
    • Dysfibrinogenemia and thrombosis
    • Mosesson MW. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost 1999; 25: 311-9.
    • (1999) Semin Thromb Hemost , vol.25 , pp. 311-319
    • Mosesson, M.W.1
  • 12
    • 0027520668 scopus 로고
    • Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis
    • Parise P, Morini M, Agnelli G, et al. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis. Blood Coagul Fibrinolysis 1993; 4: 721-7.
    • (1993) Blood Coagul Fibrinolysis , vol.4 , pp. 721-727
    • Parise, P.1    Morini, M.2    Agnelli, G.3
  • 13
    • 0026631285 scopus 로고
    • The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model
    • Bacher P, Welzel D, Iqbal O, et al. The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. Thromb Res 1992; 66: 151-8.
    • (1992) Thromb Res , vol.66 , pp. 151-158
    • Bacher, P.1    Welzel, D.2    Iqbal, O.3
  • 14
    • 0042332086 scopus 로고    scopus 로고
    • Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor
    • Lisman T, Adelmeijer J, Nieuwenhuis HK, et al. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood Coagul Fibrinolysis 2003; 14: 557-62.
    • (2003) Blood Coagul Fibrinolysis , vol.14 , pp. 557-562
    • Lisman, T.1    Adelmeijer, J.2    Nieuwenhuis, H.K.3
  • 15
    • 4444277942 scopus 로고    scopus 로고
    • Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of Fondaparinux
    • Lisman T, Bijsterveld NR, Adelmeijer J, et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of Fondaparinux. J Thromb Haemost 2003; 1: 2368-73.
    • (2003) J Thromb Haemost , vol.1 , pp. 2368-2373
    • Lisman, T.1    Bijsterveld, N.R.2    Adelmeijer, J.3
  • 16
    • 0020645310 scopus 로고
    • Factors influencing fibrin gel structure
    • Okada M, Blomback B. Factors influencing fibrin gel structure. Ann NY Acad Sci 1983; 408: 233-53.
    • (1983) Ann NY Acad Sci , vol.408 , pp. 233-253
    • Okada, M.1    Blomback, B.2
  • 17
    • 0034725622 scopus 로고    scopus 로고
    • Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation
    • Wang W, Nagashima M, Schneider M, et al. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem 2000; 275: 22942-7.
    • (2000) J Biol Chem , vol.275 , pp. 22942-22947
    • Wang, W.1    Nagashima, M.2    Schneider, M.3
  • 18
    • 0032728127 scopus 로고    scopus 로고
    • Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: Influence of plasma biochemical modifications: A possible mechanism for the high thrombotic tendency?
    • Collet JP, Mishal Z, Lesty C, et al. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications: a possible mechanism for the high thrombotic tendency? Thromb Haemost 1999; 82: 1482-9.
    • (1999) Thromb Haemost , vol.82 , pp. 1482-1489
    • Collet, J.P.1    Mishal, Z.2    Lesty, C.3
  • 19
    • 0026491075 scopus 로고
    • The effect of fibrin structure on fibrinolysis
    • Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267: 24259-63.
    • (1992) J Biol Chem , vol.267 , pp. 24259-24263
    • Gabriel, D.A.1    Muga, K.2    Boothroyd, E.M.3
  • 21
    • 0010513386 scopus 로고
    • Heparin binding sites are located in a 40-kD gamma-chain and a 36-kD beta-chain fragment isolated from human fibrinogen
    • Mohri H, Iwamatsu A, Ohkubo T. Heparin binding sites are located in a 40-kD gamma-chain and a 36-kD beta-chain fragment isolated from human fibrinogen. J Thromb Thrombolysis 1994; 1: 49-54.
    • (1994) J Thromb Thrombolysis , vol.1 , pp. 49-54
    • Mohri, H.1    Iwamatsu, A.2    Ohkubo, T.3
  • 22
    • 0029847785 scopus 로고    scopus 로고
    • Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin beta chain
    • Odrljin TM, Shainoff JR, Lawrence SO, et al. Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin beta chain. Blood 1996; 88: 2050-61.
    • (1996) Blood , vol.88 , pp. 2050-2061
    • Odrljin, T.M.1    Shainoff, J.R.2    Lawrence, S.O.3
  • 23
    • 0037663710 scopus 로고    scopus 로고
    • Interaction of fibrin(ogen) with heparin: Further characterization and localization of the heparin-binding site
    • Yakovlev S, Gorlatov S, Ingham K, et al. Interaction of fibrin(ogen) with heparin: further characterization and localization of the heparin-binding site. Biochemistry 2003; 42: 7709-16.
    • (2003) Biochemistry , vol.42 , pp. 7709-7716
    • Yakovlev, S.1    Gorlatov, S.2    Ingham, K.3
  • 24
    • 0036396028 scopus 로고    scopus 로고
    • Fondaparinux sodium mechanism of action: Identification of specific binding to purified and human plasma-derived proteins
    • Paolucci F, Clavies MC, Donat F, et al. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 2002; 41: 11-8.
    • (2002) Clin Pharmacokinet , vol.41 , pp. 11-18
    • Paolucci, F.1    Clavies, M.C.2    Donat, F.3
  • 25
    • 2642617786 scopus 로고    scopus 로고
    • Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide
    • Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-205.
    • (1998) Blood , vol.91 , pp. 4197-4205
    • Herbert, J.M.1    Herault, J.P.2    Bernat, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.